Screener
Xeris Biopharma Holdings, Inc. XERS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001867096-26-000030
FAQ
- What is Xeris Biopharma Holdings, Inc.'s debt-to-equity?
- Xeris Biopharma Holdings, Inc. (XERS) reported debt-to-equity of 19.9× in Q1 2026.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s debt-to-equity?
- Over 3 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s debt-to-equity has grown at a 94.1% compound annual growth rate (CAGR), from 2.6× to 18.9×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Xeris Biopharma Holdings, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude